Pharming narrows 2026 revenue guidance to USD 380 million–390 million
PHAR•Pharming Group narrowed its 2026 revenue guidance to US$380 million–US$390 million and cut its operating expense outlook to US$310 million–US$315 million. Preliminary third-quarter revenue rose 21% year over year to approximately US$117.6 million.
1. Guidance and quarterly results
Pharming Group narrowed its 2026 revenue guidance from US$375 million–US$395 million to US$380 million–US$390 million, and lowered its operating expense guidance from US$315 million–US$320 million to US$310 million–US$315 million. Preliminary third-quarter revenue rose 21% year over year to approximately US$117.6 million, exceeding analyst expectations; operating expenses were approximately US$74.6 million, broadly unchanged year over year and below analyst consensus. Revenue growth reflected recovering US demand for RUCONEST, more US patients receiving paid Joenja therapy and increased international demand.
